Entry Point Capital, LLC Mannkind Corp Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding MNKD
# of Institutions
219Shares Held
133MCall Options Held
1.43MPut Options Held
851K-
Black Rock Inc. New York, NY22.6MShares$134 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.4MShares$91.5 Million0.0% of portfolio
-
Nitorum Capital, L.P. New York, NY10.1MShares$59.8 Million5.97% of portfolio
-
State Street Corp Boston, MA9.56MShares$56.7 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.76MShares$51.9 Million0.62% of portfolio
About MANNKIND CORP
- Ticker MNKD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 257,338,000
- Market Cap $1.53B
- Description
- MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...